Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 1, 2017

BioPharm International

  • BioPharm International-04-01-2017
  • Volume 30
  • Issue 4

Cannabis Analyzer for Quantitative Determination of Cannabinoid Content

The Cannabis Analyzer for Potency from Shimadzu Scientific Instruments (SSI) is a high-performance liquid chromatograph (HPLC) specifically for quantitative determination of cannabinoid content.

The Cannabis Analyzer for Potency from Shimadzu Scientific Instruments (SSI) is a high-performance liquid chromatograph (HPLC) specifically for quantitative determination of cannabinoid content. The analyzer includes hardware, analytical workflows, and supplies, such as an analytical column, guard columns, mobile phase, and a certified reference materials standard mixture. The analyzer’s workflows address three analysis goals: high sample throughput, enhanced sensitivity, and resolving power for cannabinoid targets. The High Throughput method package is designed for the quantitative potency determination of the 10 cannabinoids of greatest interest in less than eight minutes per sample. The package adds tetrahydrocannabivarin to the target analyte list, with a 10-minute analysis time. The package presents full baseline resolution for all 11 compounds in less than 30 minutes and offers the ability to expand the target list as regulations change.

Shimadzu Scientific Instruments


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.